SEC Form 4 · accession 0001225208-19-004340
BOSTON SCIENTIFIC CORP · BSX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin J. Ballinger
Officer — EVP & Pres, Interven Cardio
Period of report
Mar 1, 2019
Accepted (ET)
Mar 4, 2019 · 4:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000885725
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Mar 1, 2019 | S | 20,900 | $40.7441 | D | 77,572 | D | |
| Common StockF4,F3 | Mar 3, 2019 | M | 3,302 | $0.00 | A | 80,874 | D | |
| Common StockF3 | Mar 3, 2019 | F | 1,506 | $40.75 | D | 79,368 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Stock UnitsF4,F5 | — | Mar 3, 2019 | M | 3,302 | D | — | Mar 3, 2022 | Common Stock | 3,302 | 9,909 | D |
Explanation of responses
- F1This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.
- F2Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $40.74 to $40.76, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
- F4Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
- F5Shares of common stock will be issued to the reporting person in five equal annual installments beginning on March 3, 2018, the first anniversary of the date of grant.